ArticleFrontiers in medicine2025
Yinma Jiedu granules combined with antibacterial drugs for patients with community-acquired pneumonia: protocol for a multicenter, randomized, double-blind, placebo-parallel controlled clinical trial.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Community-acquired pneumonia (CAP) is a severe respiratory infection that can lead to a range of health issues. Yinma Jiedu (YMJD) granules, a representative classic traditional Chinese patent medicine, are widely used in China, yet high-quality evidence regarding their efficacy in alleviating clinical symptoms remains limited. This study aims to evaluate the efficacy and safety of YMJD granules for the treatment of CAP. Methods: This multicenter, randomized, double-blind, placebo-controlled parallel clinical trial will be conducted at 11 hospitals in China, with each center enrolling patients competitively. A total of 226 CAP patients who meet the inclusion criteria will be stratified by age and then randomized in a 1:1 ratio to the intervention group ( Discussion: This trial is the first large-sample, randomized, double-blinded, placebo-controlled study of YMJD granules in patients for CAP. It aims to elucidate the mechanisms of early symptoms improvement, identify optimal patient populations, and informing new therapeutic strategies. Ethics and dissemination: This study design was approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (Reference Number: BF2022-306-01). Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=189230, Identifier ChiCTR2300072343.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.